Trevi Therapeutics, Inc. (TRVI) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
High 15.02 at 10:30 am ET, low 14.84 at 3:30 pm ET.
the bull case· 4
5
disclosed supplier and customer ties in SEC filings
sec filingsedgar219
managers reporting a position in thirteen f filings
13fJun 30 '26+16.27%
change in shares held by the ten largest reporting managers
13fJun 30 '263
funds on file reporting a position in TRVI
n-portas of Jun 30 '26the bear case· 4
8 of 24
largest reporting managers cut their stake in the latest quarter
13fJun 30 '2633
managers whose positions account for four fifths of reported value
13fJun 30 '260.06%
of iShares Russell two thousand ETF assets, largest fund weight on file
n-portJun 30 '268 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realizedSides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 10 '26 report. Not a forecast, not advice.
Of the 6 companies Trevi Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
TRVI (Trevi Therapeutics, Inc.) has 4 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
219 managers report a position worth $2.8B between them, and 33 of them hold 80% of it.